Journal
CLINICAL NEUROLOGY AND NEUROSURGERY
Volume 106, Issue 2, Pages 93-96Publisher
ELSEVIER
DOI: 10.1016/j.clineuro.2003.10.012
Keywords
sialorrhoea; Parkinson's disease; botulinum toxin-A; ultrasound guidance; parotid gland; saliva
Categories
Ask authors/readers for more resources
Objective: To investigate the efficacy and safety of intraparotid botulinum toxin-A (BTX-A) injections into parotid gland using ultrasoundguided versus nonguided techniques for the treatment of sialorrhoea in patients with Parkinson's disease (PD). Methods: 15 patients with PD and sialorrhoea were included and divided into two groups. Group A patients (n = 8) were injected with BTX-A using ultrasound guidance. Group B patients (n = 7) were injected with BTX-A without ultrasound guidance. Saliva secretion was assessed quantitatively at baseline and at weeks 1, 4, and 12. Patients and/or caregivers also assessed the saliva secretion using visual analog scale (VAS). Results: All patients except one reported subjective improvement in sialorrhoea at the first week. Group A patients showed significantly higher rate of saliva reduction at the first week, whereas in Group B the reduction was not statistically significant from baseline at the first week (P > 0.05). Comparisons of quantitative saliva assessments at each follow-up visit also showed that ultrasound-guided injections were superior to blind injections for saliva reduction. VAS scores showed an improvement in the mean rate of saliva secretion in each group at first week (P < 0.05). Two patients suffered from dry mouth in mild severity lasting I month. Conclusion: Intraparotid BTX-A injections using ultrasound guidance may be an effective, easy, and safe treatment for parkinsonian sialorrhoea. (C) 2003 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available